Trials / Recruiting
RecruitingNCT05435248
Phase 1/2 Study of HS-10375 in Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)
A Phase 1/2, Open-label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of HS-10375 Monotherapy in Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 354 (estimated)
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
HS-10375 is an oral, highly selective, small molecular inhibitor of EGFR C797S. This study will evaluate the safety, tolerability, pharmacokinetics and clinical activity of HS-10375 in Chinese advanced or metastatic NSCLC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HS-10375 | HS-10375 will be administered orally once daily in a continuous regimen |
Timeline
- Start date
- 2022-03-02
- Primary completion
- 2025-03-31
- Completion
- 2026-03-31
- First posted
- 2022-06-28
- Last updated
- 2024-11-04
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05435248. Inclusion in this directory is not an endorsement.